Clinical trials: FDG-PET
Ischemic Heart Disease
A Clinical Study of Evaluating Myocardial Viability in Ischemic Heart Disease with Integrated 18F-FDG PET/MR
The main purpose is to evaluate the accuracy of myocardial imaging obtained through integrated 18F-FDG PET/MR in detecting viable myocardium.
- Trial name
- NCT06712862
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai East Hospital
Disorder of Consciousness, Minimally Conscious State
Simultaneously PET/MRI in Prolonged DOC Patients
Recently introduced hybrid PET/MR scanners provide the opportunity to measure simultaneously, and in direct spatial correspondence, both metabolic demand and functional activity of the brain, hence capturing complementary…
- Conditions
- Disorder of Consciousness, Minimally Conscious State, FDG-PET, Rs-fMRI
- Trial name
- NCT04164680
- Testing
- Multimodal Neuroimaging
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hangzhou Normal University
Lung Cancer
The Role of 18F-FDG-PET/CT Scan in Lung Cancer Patients
Describe strengths and limitations of FDG PET/CT for staging. Evaluate the utility of PET/CT in assessment of therapy response and restaging
- Trial name
- NCT04395651
- Testing
- PET/CT
- Volunteers
- 30 people
- Sponsor
- Assiut University
Short-Term Renal-Hematologic Safety, Contrast-Enhanced MRI and FDG-PET/CT
Comparative Evaluation of Contrast-Enhanced MRI and FDG-PET/CT in Spinal Pathology: Image Quality and Short-Term Renal-Hematologic Safety
This prospective comparative observational study evaluates image quality characteristics and short-term physiological effects associated with contrast-enhanced magnetic resonance imaging (MRI) and fluorodeoxyglucose positron…
- Conditions
- Short-Term Renal-Hematologic Safety, Contrast-Enhanced MRI and FDG-PET/CT, Spinal Pathology
- Trial name
- NCT07640386
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Cairo University
Thyroid Cancer
Thyroid Cancer and (FDG)PET/CT Scan
Background and Rational (Introduction) Differentiated thyroid carcinoma (DTC) have favorable prognosis. Overall 10-year survival is 93% for papillary carcinoma, and 85% for follicular carcinoma(1).
- Trial name
- NCT04128631
- Volunteers
- 35 people
- Sponsor
- Assiut University
Fever of Unknown Origin
PLACE OF THE 18F-FDG-PET/CT IN THE DIAGNOSTIC WORKUP IN PATIENTS WITH CLASSICAL FEVER OF UNKNOWN ORIGIN (FUO)
Objective : To explore the diagnostic contribution of the 18F-FDG-PET/CT in a population of patients with classical fever of unknown origin (FUO), to precise its place in the diagnostic decision tree in a real-life setting and to…
- Trial name
- NCT04851379
- Where
- France
- Volunteers
- 44 people
- Sponsor
- University Hospital, Montpellier
Lymphoma, T-Cell, Peripheral
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma
The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F-FDG PET/CT and predict disease progression during chemotherapy or survival in PTCL.
- Trial name
- NCT03051568
- Testing
- 18F-FDG PET/CT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University Cancer Hospital & Institute
Thyroid Cancer, Recurrence
Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma
Several studies have indicated that [124I]-PET/CT or [18F]-FDG-PET/CT may be useful to locate recurrent differentiated thyroid carcinoma lesions in patients with elevated thyroglobulin levels but who do not show pathological…
- Trial name
- NCT01374659
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Korean Association of Endocrine Surgeons
Fabry Disease
Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR Study
This is a prospective observational study. All patients will initiate and maintain treatment with agalsidase alfa during the study period.
- Trial name
- NCT07235709
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Yonsei University
Testicular Germ Cell Tumor
Positron Emission Tomography in Detecting Testicle Cancer
RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to detect the extent of cancer and allow doctors to plan more effective treatment for patients who have testicle cancer.
- Trial name
- NCT00045045
- Testing
- positron emission tomography, fludeoxyglucose F 18
- Where
- 8 sites in United Kingdom
- Sponsor
- Institute of Cancer Research, United Kingdom
Sarcoma
Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Soft Tissue Sarcoma
18F-fluorodeoxyglucose (18F-FDG) has been approved by many regulatory agencies world-wide and is in widespread use in the United States, Japan and Europe.
- Trial name
- NCT00123786
- Testing
- Positron Emission Tomography
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- AHS Cancer Control Alberta
Oncologic Patients
Cost-effectiveness of FDG-PET
Evaluation of cost-effectiveness of FDG-PET for the public health system in Brazil.
- Trial name
- NCT01438164
- Volunteers
- 500 people
- Sponsor
- University of Sao Paulo
Advanced Cancer
Study of Temsirolimus, Topotecan, and Bortezomib
The goal of this clinical research study is to find the highest tolerable dose of Torisel (temsirolimus), Hycamtin (topotecan hydrochloride), and Velcade (bortezomib) that can be given, in combination, to patients with advanced…
- Trial name
- NCT00770731
- Testing
- Torisel (Temsirolimus), Hycamtin (Topotecan), Velcade (Bortezomib)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Cushing's Disease, Pituitary Adenoma
DDAVP for Pituitary Adenoma
This study is designed as a single institution trial. The study utilizes safe and clinically-validated tools for preoperative workup of patients with small pituitary tumors.
- Trial name
- NCT04569591
- Testing
- Desmopressin acetate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Cervical Cancer
Usefulness of FDG-PET for Advanced Cervical Cancer
The objective of this study is to determinate whether the adding of FDG-PET is helpful in the treatment of advanced cervical cancer with concurrent chemoradiation.
- Trial name
- NCT00146458
- Testing
- 18F-fluorodeoxyglucose positron emission tomography
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Chang Gung Memorial Hospital
Stage IIIA Non-small Cell Lung Cancer
Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation
This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET)/computed tomography (CT) in predicting chemoradiation therapy (CRT) failure in patients with stage IIIA non-small cell lung cancer (NSCLC).
- Trial name
- NCT01314677
- Testing
- positron emission tomography/computed tomography (PET/CT), fludeoxyglucose F 18
- Sponsor
- City of Hope Medical Center
Advanced Cancers
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
Primary Objective: Evaluate the agreement between radionuclide ventriculography (RNV) and gated F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in calculating left ventricular ejection…
- Trial name
- NCT00499382
- Testing
- Nuclear Medicine Cardiac Scan, PET/CT Cardiac Scan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Positron-Emission Tomography and Cone-Beam Computed Tomography
Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose
This is a single-centre, open-label, non-randomized clinical trial designed to monitor the occurrence of adverse events associated with [F-18]-FDG Injection manufactured by the Fedoruk Centre.
- Trial name
- NCT02811185
- Testing
- [F-18]-Fludeoxyglucose
- Volunteers
- 1,012 people
- Sponsor
- University of Saskatchewan
Lung Neoplasms, Gene, p53
Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?
p53 is a tumor suppressor gene which plays an important role in controlling normal cell proliferation regulation that is located on the chromosome 17 (17p13.1). It is the most common goal of genetic alteration in many tumors.
- Trial name
- NCT02309567
- Testing
- Blood Collection
- Where
- Turkey (Türkiye)
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Cumhuriyet University
Brain Tumors
Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor Activity
This study in children and young adults will compare two types of imaging, positron emission tomography ([(18)F]-DG PET) and proton magnetic resonance spectroscopy ((1)H-MRSI), to determine activity of a brain tumor or abnormal…
- Trial name
- NCT00067821
- Testing
- 2-Flourodeoxyglucose
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- National Cancer Institute (NCI)